Clinical trial
Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally…
NCT00023972 · Daiichi Sankyo, Industry · Completed
Key facts
| NCT number | NCT00023972 |
|---|---|
| Title | Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer |
| Official title | A Randomized, Open-Label, Multicenter Phase III Study Comparing the Efficacy and Safety of a Combination of Intravenous DX-8951f (Exatecan Mesylate) Plus Gemcitabine to Gemcitabine Alone in Patients With Locally Advanced or Metastatic Cancer of the Exocrine Pancreas Who Have Not Received Prior… |
| Lead sponsor | Daiichi Sankyo, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | exatecan mesylate, gemcitabine hydrochloride |
| Start date | Jul 1, 2001 |
| Primary completion | Apr 1, 2005 |
| Completion | Apr 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | May 16, 2012 |
| Countries | Canada, Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: